期刊文献+

丹参酚酸B山楂黄酮联用对大鼠非酒精性脂肪性肝病相关因素的干预作用 被引量:8

Effectiveness of Salvianolic acid B and Hawthorn flavone on nonalcohol fatty liver disease related factors
原文传递
导出
摘要 [目的]探讨中药成份复方(丹参酚酸B、山楂黄酮)对大鼠非酒精性脂肪性肝病相关因素的影响。[方法]大鼠被随机分为:①正常对照组,普通鼠饲料喂养;②模型组,高脂饲料喂养;③中药预防组,高脂饲料喂养的同时加每天1次灌服丹参酚酸B(200mg/kg)和山楂黄酮(40mg/kg);④中药治疗组,高脂饲料喂养4周后加每天1次灌服丹参酚酸B(200mg/kg)和山楂黄酮(40mg/kg);⑤西药组:高脂饲料喂养4周后加每天1次灌服二甲双胍片(0.5g/kg)。实验共12周。[结果]①12周时中药预防组大鼠血清脂联素含量较模型组显著升高(P<0.01);②各组大鼠血清游离脂肪酸和肿瘤坏死因子-α含量比较差异无统计学意义;③与模型组相比,6、8、12周时,中药预防组和中药治疗组大鼠肝组织三酰甘油含量明显降低(P<0.01)。[结论]丹参酚酸B和山楂黄酮联用对大鼠非酒精性脂肪性肝病相关因素具有干预作用。 [Objective]To assess the effectiveness of Salvianolic acid B and Hawthorn flavone on nonalcohol fatty liver disease related factors in rats. [Methods]The rats were randomly divided into five groups : ①control group fed with standard chow. ②model group fed with a high-fat diet. ③Chinese medicine prophylases group fed with a high-fat diet plus Salvianolic acid B(200 mg/kg) and Hawthorn flavone(40 mg/kg)orally once a day. ④Chinese medicine treatment group, in which rats were fed with a high-fat diet for 4 weeks,and then Salvianolic acid B(200 mg/kg)and Hawthorn flavone(40 mg/kg)were orally given once a day. @western medicine treatment group, in which rats were fed with a high-fat diet for 4 weeks,Metformin Tablets(0.5 g/kg)were added orally once a day for total 12 weeks. [Results] ① The sera level of adiponectin was significantly higher in Chinese medicine prophylases group than model group after 12-week-treatment (P~ 0.01). (~) No difference was found in the sera level of free fatty acids(FFA)and tumor necrosis factor-α(TNF-α) in all groups at any time. ② Comparing with model group, triglyceride (TG)in rats liver of Chinese medicine prophylases group or Chinese medicine treatment group notably reduced in 6,8,12 weeks. [Conclusion]Salvianolic acid B and Hawthorn flavone have the effect on nonalcohol fatty liver disease related factors.
出处 《中国中西医结合消化杂志》 CAS 2012年第6期245-248,共4页 Chinese Journal of Integrated Traditional and Western Medicine on Digestion
基金 上海市卫生局课题(No:2008219)
关键词 非酒精性脂肪性肝病 丹参酚酸B 山楂黄酮 大鼠 nonalcohol fatty liver disease salvianolic acid B hawthorn flavone rats
  • 相关文献

参考文献16

  • 1DAY C P,JAMES O F. Steatohepatitis: a tale of two "hits"? [J]. Gastroenterology, 1998,114:842-845.
  • 2薛冬英,陈一奕,叶军.丹参酚酸B和山楂黄酮联用对大鼠非酒精性脂肪性肝病脂质过氧化损伤的影响[J].中国中西医结合消化杂志,2011,19(6):373-377. 被引量:8
  • 3YAMAGUCHI K, YANG L, McCALL S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis [ J ]. Hepatology, 2007,45:1366-1374.
  • 4McCLAIN C J, BARVE S, DEACIUC I. Good fat/bad fat[J]. Hepatology, 2007,45: 1343- 1346.
  • 5FELDSTEIN A E, WERNEBURG N W, CANBAY A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway [J]. Hepatology, 2004,40 : 185- 194.
  • 6SHOELSON S E, LEE J, GOLDFINE A B. Inflammation and insulin resistance[J]. J Clin Invest,2006,116: 1793-1801.
  • 7LI Y,XU C,YU C,et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study[J]. J Hepatol, 2009,50 : 1029-1034.
  • 8LI Z, YANG S, LIN H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease[J]. Hepatology, 2003, 37:343-350.
  • 9XU A, WANG Y, KESHAW H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalco- holic fatty liver diseases in mice[J]. J Clin Invest, 2003,112 : 91- 100.
  • 10HUI J M, HODGE A, FARRELL G C, et al. Beyond insulin resistance in NASH :TNF-alpha or adiponectin? [J]. Hepatology, 2004,40 : 46-54.

二级参考文献12

  • 1陈佳,宋少江.山楂的研究进展[J].中药研究与信息,2005,7(7):20-23. 被引量:56
  • 2TARGHER G, BERTOLINI L, POLI F, et al. Nonal- coholic fatty liver disease and risk of future cardiovas- cular events among type 2 diabetic patients[J]. Diabetes, 2005,54 : 3541- 3546.
  • 3ARTHUR J, McCULLOUGH M D. Pathophysiology of nonalcoholic steatohepatitis [J]. J Clin Gastroen- terol, 2006,40 : S17-S29.
  • 4ANGULO P. Nonalcoholic fatty liver disease [J]. N Engl J Med,2002,16:1221-1231.
  • 5ESTEP J M, BIRERDINC A, YOUNOSSI Z. Non-inva- sive diagnostic tests for non-alcoholic fatty liver dis- ease[J]. Curr Mol Med, 2010,10.. 166- 172.
  • 6HASHIMOTO E, TOKUSHIGE K. Prevalence, gen- der, ethnic variations, and prognosis of NASH [J]. J Gastroenterol, 2011,46(Suppl 1) : 63-69.
  • 7DIXON J B, BHATHAL P S, O'BRIEN P E. Nonalco- holic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese[J].Gastroenterology, 2001,121 : 91- 100.
  • 8DELGAUDIO A, BOSCHI L. Liver damage in obese persons[J]. Obes Surg, 2001,11 :254- 257.
  • 9WESTON S R, LEYDEN W,MURPHY R, et al. Ra- cial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease[J]. Hepatology, 2005,41 :372- 379.
  • 10McCULLOUGH A J. Pathophysiology of nonalcoholic steatohepatitis[J]. Clin Gastroenterol, 2006,40 (3 Sup- pl 1) :S17-29.

共引文献7

同被引文献152

引证文献8

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部